TY - JOUR T1 - Coagulation factors and COVID-19 severity: Mendelian randomization analyses and supporting evidence JF - medRxiv DO - 10.1101/2020.11.20.20235440 SP - 2020.11.20.20235440 AU - Yao Zhou AU - Zipeng Liu AU - Hongxi Yang AU - Jianhua Wang AU - Tong Liu AU - Kexin Chen AU - Yaogang Wang AU - Pak Chung Sham AU - Ying Yu AU - Mulin Jun Li Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/12/03/2020.11.20.20235440.abstract N2 - Background The evolving pandemic of COVID-19 is arousing alarm to public health. According to epidemiological and observational studies, coagulopathy was frequently seen in severe COVID-19 patients, yet the causality from specific coagulation factors to COVID-19 severity and the underlying mechanism remain elusive.Methods First, we leveraged Mendelian randomization (MR) analyses to assess causal relationship between 12 coagulation factors and severe COVID-19 illness based on two genome-wide association study (GWAS) results of COVID-19 severity. Second, we curated clinical evidence supporting causal associations between COVID-19 severity and particular coagulation factors which showed significant results in MR analyses. Third, we validated our results in an independent cohort from UK Biobank (UKBB) using polygenic risk score (PRS) analysis and logistic regression model. For all MR analyses, GWAS summary-level data were used to ascertain genetic effects on exposures against disease risk.Results We revealed that genetic predisposition to the antigen levels of von Willebrand factor (VWF) and the activity levels of its cleaving protease ADAMTS13 were causally associated with COVID-19 severity, wherein elevated VWF antigen level (P = 0.005, odds ratio (OR) = 1.35, 95% confidence interval (CI): 1.09-1.68 in the Severe COVID-19 GWAS Group cohort; P = 0.039, OR = 1.21, 95% CI: 1.01-1.46 in the COVID-19 Host Genetics Initiative cohort) and lowered ADAMTS13 activity (P = 0.025, OR = 0.69, 95% CI: 0.50-0.96 in the Severe COVID-19 GWAS Group cohort) lead to increased risk of severe COVID-19 illness. No significant causal association of tPA, PAI-1, D-dimer, FVII, PT, FVIII, FXI, aPTT, FX or ETP with COVID-19 severity was observed. In addition, as an independent factor, VWF PRS explains a 31% higher risk of severe COVID-19 illness in the UKBB cohort (P = 0.047, OR per SD increase = 1.31, 95% CI: 1.00-1.71). In combination with age, sex, BMI and several pre-existing disease statues, our model can predict severity risks with an AUC of 0.70.Conclusion Together with the supporting evidence of recent retrospective cohort studies and independent validation based on UKBB data, our results suggest that the associations between coagulation factors VWF/ADAMTS13 and COVID-19 severity are essentially causal, which illuminates one of possible mechanisms underlying COVID-19 severity. This study also highlights the importance of dynamically monitoring the plasma levels of VWF/ADAMTS13 after SARS-CoV-2 infection, and facilitates the development of treatment strategy for controlling COVID-19 severity and associated thrombotic complication.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by grants from the National Natural Science Foundation of China 32070675, 31871327 (M.J.L.), Natural Science Foundation of Tianjin 19JCJQJC63600 (M.J.L.). Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:GWAS summary data from the Severe COVID-19 GWAS Group and the COVID-19 Host Genetics Initiative are publicly available. The UKBB COVID-19 information including genotypes, individual clinical information are granted by UKBB, the approved project is "Identification and validation of causal variants effect on cardiovascular disease through immune-mediated inflammation", project ID: 44482All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yes1. Explicit statement that approval was received to use the data in the present work or that the access to the data was granted after registration. #Response: GWAS summary data from the Severe COVID-19 GWAS Group and the COVID-19 Host Genetics Initiative are publicly available. The UKBB COVID-19 information including genotypes, individual clinical information are granted by UKBB, the approved project is "Identification and validation of causal variants effect on cardiovascular disease through immune-mediated inflammation". 2. Additional details (e.g. approval code / registration ID#), if applicable #Response: The UKBB COVID-19 project granted ID: 44482. 3. Statement about the ethics oversight body that gave ethical approval for the collection of the original data. #Response: All ethical approval for the collection of the original data is declared by UKBB and we comply with the UKBB data usage restriction. ER -